Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edesa Biotech, Inc. (EDSA : NSDQ)

• Company Description    Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $2.07 Daily Weekly Monthly 20 Day Moving Average: 12,076 shares Shares Outstanding: 7.02 (millions) Market Capitalization: $14.54 (millions) Beta: 0.39 52 Week High: $5.59 52 Week Low: $1.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.88% 1.92% 12 Week -8.41% -22.96% Year To Date 23.21% 15.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 SPY COURT - MARKHAM,A6 L3R 5H6 CAN ph: 289-800-9600 fax: 805-488-2889 investors@edesabiotech.com http://www.edesabiotech.com

• General Corporate Information    Officers Pardeep Nijhawan - Chief Executive Officer; Corporate Secretary and D Carlo Sistilli - Chairman Joan Chypyha - Director Sean MacDonald - Director Patrick Marshall - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 27966L306 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 7.02 Most Recent Split Date: 10.00 (0.14:1) Beta: 0.39 Market Capitalization: $14.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.28% vs. Previous Quarter: 37.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -187.01 12/31/24 - -233.69 ROA 06/30/25 - - 03/31/25 - -78.72 12/31/24 - -124.14 Current Ratio 06/30/25 - - 03/31/25 - 15.72 12/31/24 - 1.09 Quick Ratio 06/30/25 - - 03/31/25 - 15.72 12/31/24 - 1.09 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.90 12/31/24 - 0.37 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©